Combination Therapy Targeting the Elevated Interleukin-6 Level Reduces Invasive Migration of BRAF Inhibitor-Resistant Melanoma Cells

Molecular Oncology - Netherlands
doi 10.1002/1878-0261.12433
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells

Clinical Cancer Research
Cancer ResearchOncology
2019English

Antitumor Activity of the Selective Pan-Raf Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma

Cancer Research
Cancer ResearchOncology
2013English

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma

Cancers
Cancer ResearchOncology
2019English

Why Do We Need a New BRAF-MEK Inhibitor Combination in Melanoma?

Oncology in Clinical Practice
Oncology
2019English

Tyrphostin AG1296, a Platelet-Derived Growth Factor Receptor Inhibitor, Induces Apoptosis, And reduces Viability and Migration of PLX4032-resistant Melanoma Cells

OncoTargets and Therapy
OncologyPharmacology
2015English

Luteolin Reduces the Invasive Potential of Malignant Melanoma Cells by Targeting Β3 Integrin and the Epithelial-Mesenchymal Transition

Acta Pharmacologica Sinica
MedicinePharmacology
2012English

Ineffective Anti PD-1 Therapy After BRAF Inhibitor Failure in Advanced Melanoma

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Combination Therapy With BRAF and MEK Inhibitors for Melanoma: Latest Evidence and Place in Therapy

Therapeutic Advances in Medical Oncology
Oncology
2015English

Combination of Amino Acids Reduces Pigmentation in B16F0 Melanoma Cells

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy